Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Most Cited Paper
in Immunotherapy and Immune Responses
18 Months Post-Publication
Class of 2026
“Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/
Topics
H3K27M-mutant diffuse midline gliomas · disialoganglioside GD2 · GD2-CAR T cells · diffuse intrinsic pontine glioma · spinal diffuse midline glioma · intravenous administration · intracerebroventricular infusion · Lymphodepletion · Dose-limiting toxicity · cytokine release syndrome · tumor inflammation-associated neurotoxicity · volumetric tumor reduction · complete response · neurological benefit · clinical improvement score · autologous CAR T cell therapy · maximally tolerated dose
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-20. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459